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Background: Menstrual-related migraine is a common form of migraine affecting >50% of female migraineurs.
Acupuncture may be a choice for menstrual-related migraine, when pharmacological prophylaxis is not suitable.
However, the efficacy of acupuncture has not been confirmed. We design and perform a randomized controlled
clinical trial to evaluate the efficacy of acupuncture compared with naproxen in menstrual-related migraine patients.
Methods/Design: This is a multicenter, single blind, randomized controlled clinical trial. A total of 184 participants
will be randomly assigned to two different groups. Participants will receive verum acupuncture and placebo
medicine in the treatment group, while participants in the control group will be treated with sham acupuncture
and medicine (Naproxen Sustained Release Tablets). All treatments will be given for 3 months (menstrual cycles).
The primary outcome measures are the change of migraine days inside the menstrual cycle and the proportion of
responders (defined as the proportion of patients with at least a 50% reduction in the number of menstrual
migraine days). The secondary outcome measures are the change of migraine days outside the menstrual cycle,
duration of migraine attack, the Visual Analogue Scale (VAS), and intake of acute medication. The assessment will
be made at baseline (before treatment), 3 months (menstrual cycles), and 4 months (menstrual cycles) after the first
acupuncture session.
Discussion: The results of this trial will be helpful to supply the efficacy of acupuncture for menstrual-related
migraine prophylaxis.
Trial registration: ISRCTN: ISRCTN57133712Background
Migraine is a common neurological disorder. Population-
based studies suggest that 6% to 7% of men and 15% to
18% of women experience migraine [1,2]. More than 50%
of female patients report that their migraines are associ-
ated with the menses [3]. Attack onset is usually before
the age of 20 years, with peak prevalence between the ages
of 25 and 55 years, declining with menopause [4-6]. In-
creasing evidence links menstrual migraine to the female
sex hormones [3,7].* Correspondence: wlp5558@sina.com
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reproduction in any medium, provided the orApproximately 14% of female migraineurs have mi-
graine only during menstruation (pure menstrual mi-
graine (PMM)) while 60% suffer from migraine at both
menses and other times during the menstrual cycle
(menstrual-related migraine (MRM)) [8]. Most of the
data in the literature report that MRM causes signifi-
cant limitations of daily activities (for example, nausea,
vomiting, and photo-phonophobia), and the attacks are
generally longer, more severe, and less drug-responsive
than non-menstrual ones [9,10].
Given the particular clinical picture that characterizes
MRM, it is not surprising that the attacks are difficult to
treat. The options available for the treatment of MRM in-
clude acute therapy and prophylaxis (short-term prevent-
ive therapy and long-term preventive therapy) [11-14].Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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predictability, treatment can be targeted to the period of
time when patients are most likely to experience migraine.
The treatment window for menstrual migraine occurs be-
tween 2 days before and 3 days after the onset of menses
[12]. The goals of prophylactic strategies are to reduce at-
tack frequency, severity and duration, improve responsive-
ness of treatment for acute attacks, improve function, and
reduce disability [13]. Prophylactic medications include
non-steroidal anti-inflammatory drugs (NSAIDs), triptans,
estrogen, magnesium, dihydroergotamine (DHE), meth-
ysergide, and vitamin E [14]. Caution should be taken
when the drug is used within the same month for treating
migraine attacks occurring during menses and outside the
menstrual period due to the risk of medication-overuse
headache, a risk which is, however, common to all
medications used for menstrual-migraine prophylaxis
or treatment [14].
Acupuncture, which is one of the main treatment
modalities of Traditional Chinese Medicine (TCM),
has been used for both the prevention and treatment
of diseases for over 2,000 years. Several studies [15-18]
have already reported the encouraging results in the
therapy for migraine by acupuncture. A German ran-
domized controlled trial (n = 794) showed that 11 acu-
puncture treatments given within 6 weeks were at least
as effective as a β-blocker taken daily over 6 months
[15]. Yang et al. found that acupuncture treatment was
more effective and safer than topirmarate [16]. Wang
and co-authors reported that acupuncture was more
effective than flunarizine in decreasing the duration of
migraine attacks [17]. Therefore, acupuncture should
be considered as an option for patients with migraine
[18]. Although the physiological mechanism is still
unclear [19], in the last 40 years, many theoretically
plausible models have been developed, such as the
principle of counter-irritation diffuse noxious inhibitory
control (DNIC) and the endorphin hypothesis Melzack’s
gate control theory [20-22]. DNIC is regarded as a possible
factor explaining central pain modulation through acu-
puncture [23,24]. The endorphin hypothesis serves to
explain a short-term analgesic effect of acupuncture,
which is considered very robust.
However, based on a review of published literatures,
the guidelines did not make treatment recommendation
for acupuncture, because this therapy lacked adequate
randomized controlled trials to support its effect [25].
When reviewing the evidence of acupuncture for MRM,
only one published randomized controlled trial could be
found [26]. The objectives of that study were to introduce
a new method for controlled trials of acupuncture for
headache and to examine the role of needling per se. No
significant differences were found between the verum
group and the placebo group.In this study, we will perform a randomized controlled
trial to investigate the efficacy of acupuncture treatment
as prophylaxis for MRM.
Methods/Design
Ethics
The trial protocol is in accordance with the princi-
ples of the Declaration of Helsinki and has been ap-
proved by the Research Ethical Committee of Beijing
Hospital of Traditional Chinese Medicine Affiliated
to Capital Medical University on 10 May 2012 (ref:
201212). This trial was registered at Current Controlled
Trials (ISRCTN57133712). Each participant will be noti-
fied regarding the study protocol. Written informed con-
sent will be obtained from each participant.
Participants
Population
A target sample of 184 participants will be recruited in
acupuncture clinic from the following four hospitals:
Beijing Traditional Chinese Medicine Hospital Affiliated
to Capital Medical University, Peking University Third
Hospital, Beijing Tiantan Hospital Affiliated to Capital
Medical University, and Xiyuan Hospital affiliated with
China Academy of the Chinese Medical Sciences. The
trial will be exercised from December 2011 to December
2013.
Sample size
According to the previous pilot study [27], the number
of migraine days after treatment in acupuncture group is
3.1 ± 2.7 days, and the control group is 5.2 ± 4.4 days.
Based on 0.8 power to detect a significant difference
(α = 0.01, two-sided), 73 participants will be required for
each group, which is calculated by PASS 2008. Allowing
for a 20% withdrawal rate, we will plan to enroll a total
of 184 participants with 92 participants in each group.
Recruitment of participants
Two strategies will be used to recruit participants with
MRM. One is to recruit participants in outpatient clinics
from the four hospitals mentioned above. The other is
to show recruitment posters outside the clinics. The
posters will contain brief introductions about the popu-
lation needed to be involved, the free acupuncture treat-
ments offered to eligible participants, and the contact
information of the researcher.
Baseline assessment
A baseline registration will be undertaken before treat-
ment. At baseline, participants will be required to provide
a review of migraine history covering at least the preced-
ing 3 months (menstrual cycles), medical history in gen-
eral, and the latest medication history.
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Participants who meet all the following requirements
will be allowed for enrollment:
1. Diagnosis of MRM [28]: MRM without aura (code
A1.1.2), in which migraine without aura always
occurs on days 1 ± 2 of menstruation in at least two
out of three menstrual cycles, and at other times
due to different triggering factors or for no apparent
specific reason (International Classification of
Headache Disorders - second edition [ICHD-II])
2. Regular menstrual cycle
3. Predictable onset of inside-cycle migraine
4. Repeated migraine attacks, frequency of non-
menstrual migraine is more than once a month
5. Written informed consent
Exclusion criteria
1. Chronic migraine, tension-type headache, cluster
headache, and other primary headaches
2. Secondary headache and other neurological diseases
3. Relatively severe systemic diseases (cardiovascular
disease, acute infectious disease, hematopathy,
endocrinopathy, allergy, and methysis)
4. Headache caused by otorhinolaryngology diseases or
intracranial pathological changes
5. Oral contraceptives, pregnancy, or lactation period
6. Use of prophylactic migraine medication in the last
3 months
7. Participation in another clinical trial
Randomization and blinding
This is a multicenter (four hospitals in China), random-
ized controlled clinical trial. The central randomization
will be performed by the Research Center of Clinical
Epidemiology affiliated to Peking University in China,
which use block randomization to generate the random
allocation sequence and prepare predetermined computer-
made randomization opaque sealed envelopes. The enve-
lopes will be numbered consecutively and connected into
a strain. Each envelope will be separated from the strain
and then opened in sequence only after baseline period
when the participants are registered in the trial.
In this study, the participants will be informed that they
have a 50% chance of being allocated in either of the two
groups: verum acupuncture plus placebo medication
group and sham acupuncture plus true medication group.
The placebo medication will be identical to true medica-
tion and sham acupuncture will produce same stimulation
as verum acupuncture; hence participants will be blinded
to the group allocation. A credibility of blinding test will
be carried out in the middle of treatment phase and at the
end of treatment phase. Furthermore, outcome assessorsand personnel who will deal with data collection and data
analysis will be blinded throughout the entire trial. The
acupuncturist cannot be blinded due to the nature of the
intervention, but they will be trained not to communicate
with the participants or outcome assessors regarding treat-
ment procedures and responses.
Procedure
According to the predetermined randomization enve-
lopes, participants will be randomly allocated to acu-
puncture group or control group (see Additional file 1:
Figure S1). Participants will be asked to record head-
aches and usage of acute medication in a headache diary
from the baseline period to the fourth month (men-
strual cycle) after randomization. The headache diary
will be collected separately from four hospitals in the
fourth month (menstrual cycle) after randomization by
blinded telephone interviewers (see Additional file 2:
Table S1).
Interventions
Interventions are selected according to records in ancient
and modern books and results of previous research about
treating migraine with acupuncture [17,27]. All partici-
pants will go through a standardized interview and receive
more information about the study. Acupuncturists for
both groups have >20 years of clinical experience and an
acupuncture license from the Chinese medicine practi-
tioner license from the Ministry of Health of the People’s
Republic of China. Before performing this trial, all acu-
puncturists will receive special training about the purpose
and content of the trial, treatment strategies, and quality
control. The treatments are fully documented in accord-
ance with the STRICTA [29] and good clinical practice
guidelines (GCP).
All participants will receive treatment for 3 months
(menstrual cycles). In the treatment group, participants
will receive two acupuncture sessions per week (including
during menstruation) for preventive treatment on migraine,
and at least three additional acupuncture sessions for
premenstrual conditioning during 10 days before menstru-
ation, while placebo medicine will be given. In the control
group, participants will be given medicine (Naproxen
Sustained Release Tablets) and two sham acupuncture
sessions per week.
Each session will last for 30 min. The number of nee-
dles will be from 10 to 12 in each session for both
groups. Sterile needles for single use (Hwato Needles,
made in Suzhou, China) are used in this trial. 30-gauge
(0.3 mm in diameter), 40 mm-long needles are used for
limb and abdomen points and 32-gauge (0.25 mm in
diameter), 25 mm-long needles for head points. All needles
will be inserted 10 to 15 mm in depth and manually manip-
ulated by rotation methods to produce a characteristic
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fers to tenseness around the needle felt by the practitioner
and numbness, distension, soreness, and heaviness around
the point felt by the patient).
The placebo medicine will have exactly the same ap-
pearance as true medicines (Naproxen Sustained Release
Tablets). Both Naproxen Sustained Release Tablets and
placebo will be taken 0.5 g once per day, from the third
day (± 1 day accepted) before menstruation comes to an
end. All participants will be permitted to treat acute
headaches as required, but the type and dosage of used
medications should be recorded in the headache diary.
The points used in the treatment group
1.1 Preventive Treatment on Migraine by Acupuncture
Main points: DU20 (Baihui), DU24 (Shenting), GB13
(Benshen), GB8 (Shuaigu), SJ20 (Jiaosun), and GB20
(Fengchi)
Additional points can be chosen according to syndrome
differentiation of meridians: Shaoyang headache (TE-GB):
SJ5 (Waiguan), GB34 (Yanglingquan); Yangming headache
(LI-ST): LI4 (Hegu), ST44 (Neiting); Taiyang headache
(SI-BL): BL60 (Kunlun), SI3 (Houxi); Jueyin headache
(PC-LR): LR3 (Taichong), GB40 (Qiuxu); Nausea and
vomiting: PC6 (Neiguan); Dysphoria and susceptibility
to rage: LR3 (Taichong)
1.2 Premenstrual Conditioning by Acupuncture
Points: KI12 (Dahe), RN3 (Zhongji), ST29 (Guilai)
The points used in the control group
To make the quantity of stimulus uniform between two
groups, the decision is made to use the same kind, size,
and number of needles for control group as for treat-
ment group. The procedure for developing the sham
acupuncture protocol contains three steps.
1. Literature search: Based on the search and analyses
of 26 ancient Chinese books of acupuncture, three
Chinese acupuncture textbooks and >100
acupuncture research literatures, the points with no
reference to therapeutic effects on headache or
menstruation have been enumerated.
2. Point selection: To avoid effects on headache and
effects of alleviating pain, the points in the head,
trunk, hands, and feet are excluded. And then 15
points (see Additional file 3: Table S2) without
effects on headache or menstruation are extracted
and these points are defined as sham points, which
will be used in the control group.
3. Sham points subgroup: 15 sham points will be
randomly assigned to three subgroups of control
groups which are labeled from B to D and will be
recorded in the predetermined computer-made
randomization sealed envelope. Each subgroup hastwo points on arms and three points on legs (see
Additional file 4: Table S3). A participant who
belongs to the control group will be assigned to one
of subgroups and the five points in this subgroup
will be used on this participant in the whole
treatment period.Outcome measures
The efficacy of acupuncture for migraine prophylaxis will
be assessed by the following primary outcome measures:
1. The change of migraine days inside the menstrual
cycle [15]
2. The proportion of responders (defined as the
proportion of patients with at least a 50% reduction
of the number of menstrual migraine days) [15]
The secondary outcome measures include:
1. The change of migraine days outside the menstrual
cycle [15]
2. Duration of migraine attack [15]
3. Visual analogue scale (VAS) for pain, ranging from 0
(no pain) to 10 (worst pain ever) [30]
4. Intake of acute medication [15]
The outcome measures above will be assessed at base-
line (before treatment), 3 months (menstrual cycles) after
the first acupuncture session, and four months (menstrual
cycles) after the first acupuncture session.
The participants will be asked to fill in headache diaries
from baseline period to the fourth month (menstrual
cycle) after randomization. In the diaries, the participants
will record on diary cards details of their migraine attacks,
including the time of headache attack and cease, intensity,
frequency, location, and cause of the headache and its
associated symptoms in each migraine attack. The par-
ticipants will document whether or not they take the
acute medicine. The name, dosage of the medicine, time
of taking medicine, time of pain relief, and side effects
of the medicine will also be recorded by the participants
if they take the medicine. The participants will also
complete calendar cards to indicate the days on which
the menstruation occurs and which they receive acu-
puncture treatment.
The participants will report the adverse events they
experience, including discomfort or bruising at the sites
of needle insertion, nausea, or feeling faint after each
treatment.
The reason for drop-out or withdrawal, as well as
the participant’s compliance, will be documented in
CRF during the 3 months of treatment and 1 month of
follow-up.
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The analyses will be performed on an intention-to-treat
basis, with missing data replaced by last measure values.
The P value for statistical significance is defined as P <0.05
in all comparisons, and all statistical testing is two-sided.
Analysis of variance (ANOVA) for repeated measures is
used to compare the two groups. Comparisons within
groups for the outcomes in each one of the time point
are done using the Tukey’s post hoc test of Multivariate
Analysis of Variance (MANOVA). As for proportions, a
chi-square test is applied. Stratified analysis within four
different centers will be performed to control confound-
ing factor if necessary.
Data analysis will be conducted by statisticians who
are independent from the research team. Every analysis
is conducted by using the SPSS software version 13.0
(SPSS, Chicago, IL, USA).
Discussion
We have presented the design and the protocol for a
randomized controlled trial of acupuncture compared
with naproxen in the prophylactic therapy for patients
with MRM. Completion of this trial will help to supply
the evidence on the efficacy of acupuncture for MRM
prophylaxis.
During the preparation period of this trial, we spent
plenty of time designing the control group, since appro-
priate control is crucial for a high-quality randomized
controlled trial. One major issue is whether sham acu-
puncture should be used. As the primary consideration
of this trial is to clarify whether acupuncture is effective
for MRM prophylaxis, we all agree that a pragmatic
design is more suitable, which requires standard care
rather than placebo controlled trials [31]. However, in
China, because of the common concept of drug depend-
ence, a large proportion of patients are unwilling to use
medication, despite a confirmed diagnosis of migraine.
Acupuncture has been commonly used in clinical practice
in China. Patients usually expect to receive acupuncture
treatment when they participate in the trial. To improve
compliance of participants, sham acupuncture will be
adopted in the control group while placebo medicine will
be used in acupuncture group.
Naproxen is a drug classified as NSAIDs, which is con-
sidered safe and effective for the prophylactic treatment of
menstrual migraine [32-34]. Therefore, we compare the
efficacy of acupuncture with naproxen, which is chosen as
a standard drug therapy.
Clinical acupuncture research is complicated for sev-
eral reasons, of which the placebo issue is the most in-
triguing one [35,36]. Therefore, the American Headache
Society (AHS) has stressed the need for developing new
methods for controlled studies of acupuncture in treating
headache [37].The choice of sham points developed in our trial is
based on international considerations about the methodo-
logical problems of sham acupuncture [38]. To avoid any
influence on MRM, we searched points without effect on
headache or menstruation from both ancient and modern
literatures. This method of selecting sham points can be
seen in Alecrim [39], nevertheless, our searching scope is
more extensive. We have searched many Chinese articles,
particularly ancient books, which have not yet been trans-
lated into English. Last but not least, there are 15 points
without effects on headache or menstruation extracted,
but only five points will be applied to each patient in con-
trol group. Points, chosen and made up as a control sub-
group, are determined by computer-made randomization.
This process of confirming sham points could further
eliminate potential effects on MRM.
However, this study has several methodological limi-
tations. Previous randomized controlled trials suggest
that there is no obvious difference between verum and
sham acupuncture groups, even though they are effect-
ive compared with no treatment [40,41]. Repetitive re-
laxation and being cared for may be the reasons. In the
present study, these factors have been standardized as
strictly as possible and the selection of sham points is
different from previously published trials. We still can-
not rule out the physiological effects of our control
intervention design. Another limitation is that the ther-
apist is not blinded in this trial. It is almost impossible
to have genuine double blinding in acupuncture trials,
because acupuncturists have to control participant’s
perception of needling. This study does not allow us to
determine whether the observed effectiveness is caused
by placebo effects, intensity of provider contact, or a
physiologic effect of needling. Therefore, a bias due to
unblinding cannot be ruled out. In addition, the sample
size in the present study is relatively small.
Trial status
The trial is currently in the recruitment phase.
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